Stockreport

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

IN8bio, Inc.  (INAB) 
PDF NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies [Read more]